RXST Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
RxSight Inc (RXST) is not a strong buy at this moment for a beginner investor with a long-term strategy. While there are some positive indicators like improving financial metrics and a potential upside in the next month, the lack of strong trading signals, bearish moving averages, and stalled sales growth make it prudent to hold off on investing until there is clearer evidence of a turnaround or stronger momentum.
The MACD is positive and expanding, indicating mild bullish momentum. However, the RSI is neutral at 50.758, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot point of 8.26, with resistance at 8.745 and support at 7.775, suggesting limited immediate upside.
Improved financial performance in Q3 2025 with a 54.88% YoY increase in net income and a 50% YoY improvement in EPS. Gross margin also increased by 11.80%, indicating better operational efficiency. Analysts have slightly raised price targets, reflecting cautious optimism.
Revenue dropped by 14.09% YoY in Q3 2025, signaling challenges in sales growth. Analysts remain neutral, citing stalled sales and the need for evidence of sustainable turnaround efforts. No significant hedge fund or insider trading activity, and no recent news to drive sentiment.
In Q3 2025, revenue declined by 14.09% YoY to $30.34M. However, net income improved by 54.88% YoY to -$9.82M, and EPS improved by 50% YoY to -0.24. Gross margin increased to 79.85%, up 11.80% YoY, indicating better cost management despite declining sales.
Analysts are neutral on the stock. William Blair initiated coverage with a Market Perform rating, citing stalled sales and the need for evidence of a turnaround. Piper Sandler raised the price target to $11 from $10 but maintained a Neutral rating. Morgan Stanley raised the price target to $10 from $9, highlighting a supportive MedTech environment but keeping an Equal Weight rating.
